Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice

Clinical and Experimental Immunology

Volumn 181, Issue 2, 2015, Pages 253-266

  Cai, Z ^a,b   Wong, C K ^a,b   Dong, J ^a,b   Chu, M ^a,b   Jiao, D ^a,b   Kam, N W ^a,b   Lam, C W K ^c   Tam, L S ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

Author keywords

Cytokines; Interleukin 35; Regulatory B cells; Regulatory T cells; Systemic lupus erythematosus

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOPROTEIN GP 130; INTERLEUKIN 10; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 35; JANUS KINASE; MESSENGER RNA; PROTEIN P35; STAT PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; IL10 PROTEIN, MOUSE; IL12RB2 PROTEIN, MOUSE; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, MOUSE; JANUS KINASE 1; PROTEIN SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BODY WEIGHT; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION; HELPER CELL; JOINT SWELLING; LEUKOCYTURIA; LYMPHADENOPATHY; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REMISSION; SIGNAL TRANSDUCTION; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; PROTEIN SUBUNIT;

ANIMALS; B-LYMPHOCYTES, REGULATORY; CYTOKINE RECEPTOR GP130; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; INTERLEUKIN-10; INTERLEUKINS; JANUS KINASE 1; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; MICE, INBRED MRL LPR; PROTEIN SUBUNITS; RECEPTORS, INTERLEUKIN-12; REMISSION INDUCTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; T-LYMPHOCYTES, REGULATORY;

EID: 84947902172     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12639     Document Type: Article

References (44)

1. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56:481-90.
2. Crispin JC, Oukka M, Bayliss G et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181:8761-6.
3. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998; 280:243-8.
4. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987; 49:273-80.
5. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101:455-8.
6. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389-400.
7. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-62.
8. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev 2008; 226:248-62.
9. Collison LW, Workman CJ, Kuo TT et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450:566-9.
10. Collison LW, Chaturvedi V, Henderson AL et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11:1093-101.
11. Collison LW, Delgoffe GM, Guy CS et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012; 13:290-9.
12. Wang RX, Yu CR, Dambuza IM et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 2014; 20:633-41.
13. Shen P, Roch T, Lampropoulou V et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014; 507:366-70.
14. Boggio E, Clemente N, Mondino A et al. IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes. Blood 2013; 123:1178-86.
15. Yu SL, Chan PK, Wong CK et al. Antagonist-mediated down-regulation of Toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. Arthritis Res Ther 2012; 14:R80.
16. Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C. Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003; 33:215-23.
17. Yang JQ, Wen X, Liu H et al. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum 2007; 56:1219-33.
18. Nozaki Y, Yamagata T, Yoo BS et al. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice. Clin Exp Immunol 2005; 139:74-83.
19. Jacob N, Yang H, Pricop L et al. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol 2009; 182:2532-41.
20. Zagury D, Le Buanec H, Mathian A et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 2009; 106:5294-9.
21. Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009; 183:3160-9.
22. Ma J, Rossini M, Yang HC, Zuo Y, Fogo AB, Ichikawa I. Effects of podocyte injury on glomerular development. Pediatr Res 2007; 62:417-21.
23. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189:1639-48.
24. Moon HW, Kim BH, Park CM et al. CD4+CD25highFoxP3+ regulatory T-cells in hematologic diseases. Korean J Lab Med 2011; 31:231-7.
25. Elkord E. Thymus-derived, peripherally derived, and in vitro-induced T regulatory cells. Front Immunol 2014; 5:17.
26. Li Y, Wang Y, Liu Y, Zuo X, Lu X. The possible role of the novel cytokines IL-35 and IL-37 in inflammatory bowel disease. Mediat Inflamm 2014; 2014:136329.
27. Niedbala W, Wei XQ, Cai B et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007; 37:3021-9.
28. Liu JQ, Liu Z, Zhang X et al. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol 2012; 188:3099-106.
29. Tirotta E, Duncker P, Oak J et al. Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis. J Neuroimmunol 2012; 254:110-6.
30. Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010; 184:7144-53.
31. Jalah R, Rosati M, Ganneru B et al. The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem 2013; 288:6763-76.
32. Hamza T, Barnett JB, Li B. Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 2010; 11:789-806.
33. Chavele KM, Ehrenstein MR. Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis. FEBS Lett 2011; 585:3603-10.
34. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21:1105-11.
35. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of Treg-mediated T cell suppression. Front Immunol 2012; 3:51.
36. Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol 2013; 4:315.
37. Kuo J, Nardelli DT, Warner TF, Callister SM, Schell RF. Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice. Clin Vaccine Immunol 2011; 18:1125-32.
38. Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol 2008; 180:6649-55.
39. Whibley N, Maccallum DM, Vickers MA et al. Expansion of Foxp3(+) T-cell populations by Candida albicans enhances both Th17-cell responses and fungal dissemination after intravenous challenge. Eur J Immunol 2014; 44:1069-83.
40. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9:589-93.
41. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127:385-93.
42. Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006; 65:209-15.
43. Yu SL, Wong CK, Wong PT et al. Down-regulated NOD2 by immunosuppressants in peripheral blood cells in patients with SLE reduces the muramyl dipeptide-induced IL-10 production. PLOS ONE 2011; 6:e23855.
44. Kinoshita M, Seki S, Ono S, Shinomiya N, Hiraide H. Paradoxical effect of IL-18 therapy on the severe and mild Escherichia coli infections in burn-injured mice. Ann Surg 2004; 240:313-20.